Sobi Exceeds 2025 Revenue and Adjusted EBITA Margin Outlook
Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO:SOBI) today announced that its full-year 2025 revenue and adjusted EBITA margin have surpassed the company’s previous outlook, reflecting strong performance across its portfolio. Full-year revenue reached approximately SEK 28.2 billion, representing around 15 percent growth at constant exchange rates (CER) compared with 2024. Adjusted EBITA margin¹,² came in at approximately 40 percent of revenue, above prior expectations.
The increase in revenue was primarily driven by higher-than-anticipated sales in the fourth quarter of 2025 for several of Sobi’s key products. Doptelet, Gamifant, and the company’s Haemophilia portfolio all recorded stronger-than-expected performance, contributing significantly to the overall growth for the year. The improved revenue, in turn, had a positive impact on profitability, boosting the adjusted EBITA margin above earlier forecasts.
At the time of its Q3 2025 report publication on 20 October 2025, Sobi had projected full-year revenue to grow by a low double-digit percentage at CER, while the adjusted EBITA margin was expected to fall in the mid to high-30s percent of revenue. The company’s stronger-than-expected results demonstrate both the resilience of its commercial strategy and the continued demand for its therapies in key markets.
The company attributes its successful performance to several factors. Strong patient uptake, effective market access strategies, and continued innovation across its product portfolio have supported growth, particularly in therapies addressing rare diseases with significant unmet medical needs. Doptelet, for example, has seen increased adoption in both established and emerging markets, while Gamifant continues to benefit from its strong clinical profile and growing recognition among healthcare professionals. The Haemophilia portfolio also contributed positively, supported by expanding treatment options and ongoing engagement with patient communities and healthcare providers.
Looking ahead, Sobi continues to focus on innovation and expansion of its pipeline, aiming to deliver transformative therapies to patients worldwide. The company’s strategy emphasizes both organic growth and strategic partnerships, with a strong focus on rare and complex diseases where its expertise can make a meaningful difference in patients’ lives.
Sobi will release its fourth quarter and full-year 2025 financial results on Thursday, 5 February 2026, at 8:00 am CET. The report will provide further details on financial performance, product sales, and progress across the company’s pipeline initiatives.
About Sobi®
Sobi is a global biopharmaceutical company dedicated to unlocking the potential of breakthrough innovations and transforming everyday life for people living with rare diseases. With a workforce of approximately 1,900 employees across Europe, North America, the Middle East, Asia, and Australia, Sobi combines scientific expertise with a patient-focused approach.
In 2024, Sobi reported revenue of SEK 26 billion, reflecting its consistent growth trajectory in the rare disease segment. The company’s diverse portfolio spans multiple therapeutic areas, including hematology, immunology, and specialty care, with a strong commitment to research, development, and commercialization of innovative treatments.
Sobi’s shares (STO:SOBI) are listed on Nasdaq Stockholm. Additional information about the company, its products, and its pipeline can be found at sobi.com and on LinkedIn.
This announcement contains forward-looking statements that reflect Sobi’s current views with respect to future events and financial performance. These statements involve risks and uncertainties that may cause actual results to differ materially from those expressed or implied. Factors that could influence outcomes include market conditions, regulatory developments, competitive pressures, and other risks described in Sobi’s filings with Nasdaq Stockholm.
Source link : https://www.sobi.com/
